- Report
- October 2024
- 181 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- April 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 131 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 137 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- July 2018
- 30 Pages
China
From €2002EUR$2,200USD£1,716GBP
- Report
- January 2022
- 60 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9101EUR$10,000USD£7,802GBP
- Report
- May 2023
- 86 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- May 2022
- 51 Pages
Global
From €1820EUR$2,000USD£1,560GBP
Epoetin Alfa is a hematological drug used to treat anemia caused by chronic kidney disease, chemotherapy, and HIV/AIDS. It is a recombinant form of erythropoietin, a hormone produced by the kidneys that stimulates the production of red blood cells. Epoetin Alfa is administered intravenously or subcutaneously and is used to reduce the need for blood transfusions in patients with anemia. It is also used to reduce the risk of death and hospitalization in patients with anemia due to chronic kidney disease.
Epoetin Alfa is a widely used drug in the hematological market, with many companies offering it as a treatment option. Some of the companies in the market include Amgen, Johnson & Johnson, Roche, Novartis, and Pfizer. Show Less Read more
